Jessica Rose

Maybe soon. So the story develops. So they're using the construct of this Venezuelan equine encephalitis virus because it carries... this gene called RDRP. That's the RNA dependent RNA polymerase that allows that virus to optimize its own survival by being able to copy its own genetic material.

Maybe soon. So the story develops. So they're using the construct of this Venezuelan equine encephalitis virus because it carries... this gene called RDRP. That's the RNA dependent RNA polymerase that allows that virus to optimize its own survival by being able to copy its own genetic material.

So like I said, instead of the, the, the virus junk and the replication machinery that they take out, they substitute in the spike gene. So that's the stuff that they put into people in Japan. Now, I'll say one more thing and then I'll tell you why I'm worried about this. So on November 11th, the FDA green lighted the phase one trialing of this exact same technology for H5N1 virus.

So like I said, instead of the, the, the virus junk and the replication machinery that they take out, they substitute in the spike gene. So that's the stuff that they put into people in Japan. Now, I'll say one more thing and then I'll tell you why I'm worried about this. So on November 11th, the FDA green lighted the phase one trialing of this exact same technology for H5N1 virus.

This is this bird flu virus that they're, they're, they're talking, they're using in the same language or they're using in the same sentence with the word pandemic. It's even in like the word pandemic is even in the title of the phase one study. And what they've done is instead of inserting spike genes, they've inserted the hemagglutinin and the neuraminidase genes from the H5N1.

This is this bird flu virus that they're, they're, they're talking, they're using in the same language or they're using in the same sentence with the word pandemic. It's even in like the word pandemic is even in the title of the phase one study. And what they've done is instead of inserting spike genes, they've inserted the hemagglutinin and the neuraminidase genes from the H5N1.

So that in and of itself is kind of scary. And here's what I'd like everyone to do now as a thought experiment and the reason why I'm concerned. So As part of the phase one trial, there's 200 people in it, 18 to 80. The inclusion criteria list was anemic. They only had three points. The exclusion criteria was also really low.

So that in and of itself is kind of scary. And here's what I'd like everyone to do now as a thought experiment and the reason why I'm concerned. So As part of the phase one trial, there's 200 people in it, 18 to 80. The inclusion criteria list was anemic. They only had three points. The exclusion criteria was also really low.

Basically, anybody who had a serious adverse reaction to the modified mRNA shots is excluded. And the inclusion criteria, this is just a point of interest to make you think, included people who were able to get pregnant If you are of childbearing age, you should protect yourself during the trials. I just want to throw that there.

Basically, anybody who had a serious adverse reaction to the modified mRNA shots is excluded. And the inclusion criteria, this is just a point of interest to make you think, included people who were able to get pregnant If you are of childbearing age, you should protect yourself during the trials. I just want to throw that there.

Nowhere in the inclusion or the exclusion criteria is there any mention of how many shots of the modified mRNA stuff they got, which begs questions about counterindications, or whether or not those people may be carrying replicating alpha viruses. Now we're going into hypothetical land here, but we have to because of something called RNA recombination, which is a real possibility here.

Nowhere in the inclusion or the exclusion criteria is there any mention of how many shots of the modified mRNA stuff they got, which begs questions about counterindications, or whether or not those people may be carrying replicating alpha viruses. Now we're going into hypothetical land here, but we have to because of something called RNA recombination, which is a real possibility here.

So imagine one of these people is infected with an alpha virus of some kind. All the alpha viruses have this RDRP gene that allows them to photocopy their own genetic material. Let's say they don't have many symptoms for some reason. So they get into the trial, they have some cells, let's say that some cells have active replication going on in them.

So imagine one of these people is infected with an alpha virus of some kind. All the alpha viruses have this RDRP gene that allows them to photocopy their own genetic material. Let's say they don't have many symptoms for some reason. So they get into the trial, they have some cells, let's say that some cells have active replication going on in them.

And this actually brings us back to that excellent point that Claire made about infection, because unless you have a very high viral load due to a lot of viral replication going on in many cells, you're not really having an infection. So let's just say you have a few cells with viral replication going on. Now, because these

And this actually brings us back to that excellent point that Claire made about infection, because unless you have a very high viral load due to a lot of viral replication going on in many cells, you're not really having an infection. So let's just say you have a few cells with viral replication going on. Now, because these

These new self-amplifying RNA guys are encapsulated in lipid nanoparticles. We know that once someone gets injected with this stuff, that it has the potential to traffic everywhere. So let's hypothesize that one of these lipid nanoparticles reaches a cell in the body that has an active replication going on of an alpha virus.

These new self-amplifying RNA guys are encapsulated in lipid nanoparticles. We know that once someone gets injected with this stuff, that it has the potential to traffic everywhere. So let's hypothesize that one of these lipid nanoparticles reaches a cell in the body that has an active replication going on of an alpha virus.

What could potentially happen here, and this is hypothetical, but it could happen, is something called RNA recombination. So during the replication cycle, there's something that the virus can do called template switching.

What could potentially happen here, and this is hypothetical, but it could happen, is something called RNA recombination. So during the replication cycle, there's something that the virus can do called template switching.